Analysts' Top 5 Price Targets of August 21, 2025
Reading Time: 4 minutes
Axsome Therapeutics [US05464T1043] RBC Capital confirms Buy rating with a price target of $189 (62% upside potential) The assessment is based on the strong financial performance of the company in the second quarter as well as the promising potential of the drug AXS-05, which is being developed for the treatment of agitation in Alzheimer’s patients. RBC emphasizes that Axsome ’s revenue of $150 million has exceeded expectations, and the loss per share was also less than anticipated. The analyst is particularly optimistic about the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
